The DESCAR-T registry was set up at the request of the health authorities to improve our knowledge of CAR T-cell therapies marketed in France to treat patients diagnosed with hematological malignancies. The objective of this registry is to collect data on the efficacy as well as on short- and long-term tolerance of these therapies in real-life setting.
Thanks to the data collected, the registry makes it possible to carry out projects to answer specific research questions. One of these projects is looking at the efficacy and safety of CAR-T cell treatments in patients treated for lymphoma and immunocompromised following post-transplant lymphoproliferative disease (PTLD) or primary immunodeficiency (PID).
Why is this study being implemented?
CAR-T cells are innovative therapies that have been offered to certain patients with lymphomas for more than five years now. Despite this, there are few data on the quality of manufactured CAR-T cells and the outcome of patients treated with these CAR-T cells in immunocompromised patients (PTLD or PID) who have relapsed or are refractory to a previous line of lymphoma treatment.
The functionality of the lymphocytes (a kind of white blood cells) collected and modified (principle of CAR-T cell therapy) in a context of immunosuppression and their activity after injection remains to be defined. The literature on the subject is very limited.
What are the objectives of the study?
The study firstly aims to evaluate the effectiveness of CAR-T cells in this particular population. Its second objective is to describe the characteristics of these patients in order to identify prognostic factors that allow for better selection of medical indications. In addition, this study aims to evaluate the feasibility of producing these therapies in a context of immunosuppression in the patient.
This study will provide the scientific and medical community with the keys to better care for immunocompromised patients with lymphoma.
How will the study be carried out?
This study is led by Dr. Emilie CORVILAIN (Saint Louis Hospital), Dr. Sylvain CHOQUET (Pitié Salpêtrière Hospital) and Dr. Morgane CHEMINANT (Necker Hospital) of the Greater Paris University Hospitals (AP-HP), and Dr Amandine FAYARD from the Clermont-Ferrand University Hospital.
The study will be based on the analysis of data from the DESCAR-T register. The analysis will be carried out by the project leaders in the first quarter of 2025. The results are expected to be presented at international lymphoma congresses and lead to a scientific article in 2025.
FOR PATIENTS WHO HAVE BEEN OFFERED CAR-T THERAPY IN FRANCE
What does this project mean for you?
This project concerns patients included in the DESCAR-T registry treated for their lymphoma with CAR-T cells and immunocompromised following post-transplant lymphoproliferative disease or primary immune deficiency.
If you are in this situation and agree for your data to be used for this project, this has no direct implications for you.
What should you do about this study?
- If you would like more information about the processing of your data in the context of DESCAR-T and this project,
Or
- or if you wish to exercise your rights regarding your data (access and rectification, limitation of their use),
⇒ inform the doctor at your hospital or centre of care for CAR T-cell therapy, who will contact LYSARC while maintaining your anonymity. You can also notify your decision by email at: dpo@lysarc.org.
- Otherwise, you don’t have to do anything.
You can find more information about your rights in relation to your data “I am participating or have participated in a trial“.